Experimental osteoporosis drug bests Lilly’s Forteo in study
The experimental medicine, called romosozumab, showed better results than Eli Lilly and Co.’s Forteo after 12 months, Amgen and UCB said in a joint statement Wednesday.
Health Care & Life Sciences
Articles
Longtime IU Health leader Evans to retire next year
Daniel Evans Jr. plans to leave his post as president immediately and retire as CEO on May 1. The system’s chief operating officer, Dennis Murphy, will take over as president now and as CEO in the spring.
Obamacare, HIP 2.0 goosing hospital profits—for now
More paying customers helped Community Health Network pull in $47 million in second-quarter profits, a story being repeated at not-for-profit hospitals around the country as Obamacare has boosted the number of insured customers to unprecedented highs.
Is Indiana’s lack of ‘narrow networks’ keeping Obamacare premiums high?
A recent study found the number of health insurers offering broad provider networks on the Obamacare exchange was higher than in all but 10 other states and suggests that so long as Hoosiers keep singing “Don’t Fence Me In,” they could keep paying more for health insurance.
Novo Nordisk buying 2 DiMarchi-launched drug firms
Calibrium LLC and MB2 LLC, both based in Carmel, have agreed to be sold for undisclosed amounts. They were developing diabetes drugs discovered by the research team of Richard DiMarchi, a chemistry professor at Indiana University.
Lilly wins patent ruling over blockbuster drug Alimta
Eli Lilly and Co. won a court ruling that will keep generic versions of the chemotherapy drug Alimta off the U.S. market until a patent expires in 2022.
YMCA partners with VA for Pike Township center
Although the $10 million Pike Township YMCA has no timetable for completion, officials have pledged to offer extensive services to veterans in conjunction with the Richard L. Roudebush VA Medical Center.
Surprising heart study could bring Lilly $1B annually
Eli Lilly and Co. didn’t win approval for a new drug last week. But its latest study of an existing diabetes drug could create a blockbuster in its own right—adding as much as $1 billion a year to the coffers of the Indianapolis-based drugmaker.
UPDATE: Why insurance mega-mergers won’t launch wave of hospital hook-ups
Profits at most county-owned hospitals have grown by 100 percent to 400 percent over the past four years via partnerships with nursing homes that have brought in hundreds of millions of dollars in extra federal money.
IU School of Dentistry gets OK for $21.6M expansion
The IU Board of Trustees gave unanimous approval to the 45,000-square-foot addition to the school at IUPUI. It is expected to open in 2020.
Regenstrief CEO Tierney to depart for Texas job
Dr. Bill Tierney, who has led the Regenstrief medical informatics research operation for five years, will become chair of the department of population health at the Dell Medical School at the University of Texas at Austin.
Lilly shares jump after positive study of diabetes drug
Lilly’s stock had its biggest intraday gain since 2009 Thursday after it announced trial results that showed Jardiance lowered the risk of heart attacks, stroke and death in a large trial of adults with type 2 diabetes.
Anthem to cover libido pill; other insurers weighing decision
Concerns about serious side effects, including fainting, complicate discussions about whether to cover Sprout Pharmaceuticals' Addyi.
FDA approves female sex pill, but with safety restrictions
The Food and Drug Administration on Tuesday approved the first prescription drug designed to boost sexual desire in women, a milestone long sought by a pharmaceutical industry eager to replicate the blockbuster success of impotence drugs for men.
Indiana to get $1.3M slice of Amgen settlement
Biotech drugmaker Amgen will pay $71 million to settle an investigation into illegal marketing of its drugs Aranesp and Enbrel, ending an investigation by 48 states and Washington, D.C.
IU Health brass pledges to boost morale after survey cites problems
According to an internal memo, employees at Indiana University Health “lack confidence in senior leadership” and don’t think they are consistently provided adequate resources to serve patients. IU Health leaders have vowed to fix that.
Indy medical device firm plans 125-job expansion
Catheter Research Inc.—which makes single-use medical devices, such as catheters—plans a $4.8 million expansion that will relocate its headquarters to larger space on the northwest side.
Indiana health care investments simmer while national market sizzles
Hoosier entrepreneurs in health care and life sciences attracted more than $31 million from investors during the first half of the year. But too few Indiana companies have developed their technology enough to attract venture capitalists or tap stock markets.
IU eyes clinical trials to boost research success
The new head of research at the Indiana University School of Medicine thinks the institution is missing out on the more than $6 billion spent each year in the United States on clinical trials.
Lack of help irks patients after medical data breach
Some patients who had their personal information compromised by a data breach at an Indiana medical software company are having trouble signing up for two years of free credit monitoring and identity protection.